Finally, it was in the 2005 McDonald criteria when aquaporin-4 (AQP4) serum antibody testing for neuromyelitis optica spectrum disorder (NMOSD) was first recommended to be performed in all cases with clinical manifestations suggestive of NMOSD [18]. The gene discussed is AQP4; the disease is neuromyelitis optica.